Literature DB >> 12903918

Reduction of potential respiratory pathogens by oral hygienic treatment in patients undergoing endotracheal anesthesia.

Minori Okuda1, Yuzuru Kaneko, Tatsuya Ichinohe, Kazuyuki Ishihara, Katsuji Okuda.   

Abstract

PURPOSE: This study was conducted to evaluate the usefulness of mechanical and chemical prophylactic oral cleansing treatments for reducing potential respiratory pathogens existing in the oral cavity.
METHODS: Thirty-two patients scheduled to undergo oral and maxillofacial surgery that required endotracheal anesthesia were randomly allocated to one of the two groups, the oral cleansing group (n = 16) or the noncleansing group (n = 16). Culture and polymerase chain reaction (PCR) methods were used to detect and enumerate pathogens. Oral cleansing was carried out with an electric toothbrush capable of automatically supplying and aspirating povidone-iodine solution before surgery, followed by rinsing twice a day after surgery. Cephazolin (3 g x day(-1)) was given to all patients for 5 days after surgery.
RESULTS: The PCR detection rates of Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, and Porphyromonas gingivalis in gargle samples before treatment were 87.5%, 68.8%, 53.1%, and 40.6%, respectively. Oral cleansing reduced the detection rates and numbers of methicillin-sensitive Staphylococcus species, S. pneumoniae, and H. influenzae. In contrast, there was no significant reduction of methicillin-resistant Staphylococcus species, S. pneumoniae, H. influenzae, or P. aeruginosa in subjects who underwent systemic cephazolin administration without oral cleansing.
CONCLUSION: The combination of mechanical and chemical oral cleansing resulted in a significant reduction of potential respiratory pathogens in the oral cavity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12903918     DOI: 10.1007/s005400300022

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  7 in total

1.  Prevotella intermedia induces severe bacteremic pneumococcal pneumonia in mice with upregulated platelet-activating factor receptor expression.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yoshitomo Morinaga; Shigeki Nakamura; Tatsuhiko Harada; Hiroo Hasegawa; Koichi Izumikawa; Yuji Ishimatsu; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Infect Immun       Date:  2013-11-18       Impact factor: 3.441

2.  Fraser syndrome-oral manifestations and a dental care protocol.

Authors:  Talita Lopes de Oliveira; Giselle Rodrigues de Sant'Anna
Journal:  Case Rep Dent       Date:  2014-12-21

3.  Porphyromonas gingivalis Components/Secretions Synergistically Enhance Pneumonia Caused by Streptococcus pneumoniae in Mice.

Authors:  Teppei Okabe; Yosuke Kamiya; Takeshi Kikuchi; Hisashi Goto; Masayuki Umemura; Yuki Suzuki; Yoshihiko Sugita; Yoshikazu Naiki; Yoshiaki Hasegawa; Jun-Ichiro Hayashi; Shotaro Kawamura; Noritaka Sawada; Yuhei Takayanagi; Takeki Fujimura; Naoya Higuchi; Akio Mitani
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

4.  In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens.

Authors:  Maren Eggers; Torsten Koburger-Janssen; Markus Eickmann; Juergen Zorn
Journal:  Infect Dis Ther       Date:  2018-04-09

Review 5.  Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections.

Authors:  J Kanagalingam; R Feliciano; J H Hah; H Labib; T A Le; J-C Lin
Journal:  Int J Clin Pract       Date:  2015-08-06       Impact factor: 2.503

Review 6.  Topical preparations to reduce SARS-CoV-2 aerosolization in head and neck mucosal surgery.

Authors:  Harman S Parhar; Kendall Tasche; Robert M Brody; Gregory S Weinstein; Bert W O'Malley; Rabie M Shanti; Jason G Newman
Journal:  Head Neck       Date:  2020-04-25       Impact factor: 3.147

7.  2-Methacryloyloxyethyl phosphorylcholine (MPC)-polymer suppresses an increase of oral bacteria: a single-blind, crossover clinical trial.

Authors:  Natsumi Fujiwara; Hiromichi Yumoto; Koji Miyamoto; Katsuhiko Hirota; Hiromi Nakae; Saya Tanaka; Keiji Murakami; Yasusei Kudo; Kazumi Ozaki; Yoichiro Miyake
Journal:  Clin Oral Investig       Date:  2018-05-16       Impact factor: 3.573

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.